S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
Log in
NASDAQ:CSBR

Champions Oncology Stock Forecast, Price & News

$11.72
+0.02 (+0.17 %)
(As of 03/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$11.11
Now: $11.72
$11.96
50-Day Range
$10.80
MA: $11.53
$12.21
52-Week Range
$4.02
Now: $11.72
$13.45
Volume34,869 shs
Average Volume28,109 shs
Market Capitalization$156.68 million
P/E RatioN/A
Dividend YieldN/A
Beta1.2
Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Technology Platform, provides Personalized Oncology Solutions (POS) that assist physicians in developing personalized treatment options for cancer patients through tumor specific data obtained from drug panels and related personalized oncology services. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. In addition, the company provides POS products, including TumorGraft implants and drug panels, which utilizes TumorGraft technology to test the response of a patient's tumor to multiple oncology drugs or drug combinations. It markets its products through internet, word of mouth, and sales force to patients and physicians. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.
Champions Oncology logo

Headlines

Champions Oncology Announces Addition to Board of Directors
February 22, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CSBR
CUSIPN/A
Phone201-808-8400
Employees143
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$32.12 million
Book Value$0.45 per share

Profitability

Net Income$-1,980,000.00

Miscellaneous

Market Cap$156.68 million
Next Earnings Date3/11/2021 (Estimated)
OptionableNot Optionable

MarketRank

Overall MarketRank

1.15 out of 5 stars

Medical Sector

928th out of 1,972 stocks

Biological Products, Except Diagnostic Industry

122nd out of 177 stocks

Analyst Opinion: 0.0Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -
$11.72
+0.02 (+0.17 %)
(As of 03/5/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CSBR News and Ratings via Email

Sign-up to receive the latest news and ratings for CSBR and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Champions Oncology (NASDAQ:CSBR) Frequently Asked Questions

What stocks does MarketBeat like better than Champions Oncology?

Wall Street analysts have given Champions Oncology a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Champions Oncology wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Champions Oncology's next earnings date?

Champions Oncology is scheduled to release its next quarterly earnings announcement on Thursday, March 11th 2021.
View our earnings forecast for Champions Oncology
.

How were Champions Oncology's earnings last quarter?

Champions Oncology, Inc. (NASDAQ:CSBR) released its quarterly earnings results on Monday, December, 14th. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, meeting the Thomson Reuters' consensus estimate of $0.01. The biotechnology company earned $10.12 million during the quarter, compared to the consensus estimate of $9.63 million. Champions Oncology had a negative trailing twelve-month return on equity of 29.93% and a negative net margin of 4.18%.
View Champions Oncology's earnings history
.

How has Champions Oncology's stock price been impacted by COVID-19?

Champions Oncology's stock was trading at $4.97 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, CSBR shares have increased by 135.8% and is now trading at $11.72.
View which stocks have been most impacted by COVID-19
.

What guidance has Champions Oncology issued on next quarter's earnings?

Champions Oncology issued an update on its FY 2021 After-Hours earnings guidance on Monday, December, 14th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $38.548-40.154 million, compared to the consensus revenue estimate of $38.56 million.

Who are Champions Oncology's key executives?

Champions Oncology's management team includes the following people:
  • Dr. Ronnie Morris, CEO & Director (Age 55, Pay $1.34M)
  • Mr. David Barry Miller M.B.A., Chief Financial Officer (Age 52, Pay $290k)
  • Dr. Philip P. Breitfeld, Chief Strategy & Innovation Officer and Director (Age 68)
  • Dr. Karin Abarca Heidemann, VP of Scientific Operations
  • Dr. Michael Ritchie M.B.A., Ph.D., Chief Commercial Officer

What is Ronnie Morris' approval rating as Champions Oncology's CEO?

8 employees have rated Champions Oncology CEO Ronnie Morris on Glassdoor.com. Ronnie Morris has an approval rating of 50% among Champions Oncology's employees. This puts Ronnie Morris in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Champions Oncology's key competitors?

What other stocks do shareholders of Champions Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Champions Oncology investors own include Gilead Sciences (GILD), Intel (INTC), Cytosorbents (CTSO), Micron Technology (MU), Corbus Pharmaceuticals (CRBP), NVIDIA (NVDA), AbbVie (ABBV), Agile Therapeutics (AGRX), CRISPR Therapeutics (CRSP) and Exelixis (EXEL).

What is Champions Oncology's stock symbol?

Champions Oncology trades on the NASDAQ under the ticker symbol "CSBR."

Who are Champions Oncology's major shareholders?

Champions Oncology's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (3.48%), Renaissance Technologies LLC (1.66%), Roubaix Capital LLC (1.54%), Millrace Asset Group Inc. (1.36%), Dimensional Fund Advisors LP (0.98%) and Northern Trust Corp (0.80%). Company insiders that own Champions Oncology stock include Daniel Newman Mendelson, Enterprise Associates 14 New, Philip P Breitfeld and Ronnie Morris.
View institutional ownership trends for Champions Oncology
.

Which major investors are selling Champions Oncology stock?

CSBR stock was sold by a variety of institutional investors in the last quarter, including Essex Investment Management Co. LLC, Globeflex Capital L P, Renaissance Technologies LLC, New York State Common Retirement Fund, Northern Trust Corp, Wells Fargo & Company MN, Charles Schwab Investment Management Inc., and Zebra Capital Management LLC. Company insiders that have sold Champions Oncology company stock in the last year include Enterprise Associates 14 New, Philip P Breitfeld, and Ronnie Morris.
View insider buying and selling activity for Champions Oncology
or view top insider-selling stocks.

Which major investors are buying Champions Oncology stock?

CSBR stock was bought by a variety of institutional investors in the last quarter, including Roubaix Capital LLC, Millrace Asset Group Inc., BlackRock Inc., and JPMorgan Chase & Co.. Company insiders that have bought Champions Oncology stock in the last two years include Daniel Newman Mendelson, and Ronnie Morris.
View insider buying and selling activity for Champions Oncology
or or view top insider-buying stocks.

How do I buy shares of Champions Oncology?

Shares of CSBR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Champions Oncology's stock price today?

One share of CSBR stock can currently be purchased for approximately $11.72.

How much money does Champions Oncology make?

Champions Oncology has a market capitalization of $156.68 million and generates $32.12 million in revenue each year. The biotechnology company earns $-1,980,000.00 in net income (profit) each year or ($0.17) on an earnings per share basis.

How many employees does Champions Oncology have?

Champions Oncology employs 143 workers across the globe.

What is Champions Oncology's official website?

The official website for Champions Oncology is www.championsoncology.com.

Where are Champions Oncology's headquarters?

Champions Oncology is headquartered at One University Plaza Suite 307, Hackensack NJ, 07601.

How can I contact Champions Oncology?

Champions Oncology's mailing address is One University Plaza Suite 307, Hackensack NJ, 07601. The biotechnology company can be reached via phone at 201-808-8400 or via email at [email protected]


This page was last updated on 3/6/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.